During the quarter, we strengthened our market position through new strategic partnerships and distribution agreements. These investments will constitute important steps towards a broader international presence and create a solid foundation for ZymIQ's continued expansion.

"Our business model is ready to be scaled up, which is shown not least by the new distribution agreements.”
Michael Edelborg Christensen,
CEO, ZymIQ Technology

1 Jan – 30 Sep 2025

• Net sales increased by 53% to SEK 1,546 thousand (1,012)
• Loss after tax amounted to SEK -6,242 thousand (-8,343)
• Earnings per share amounted to SEK -0.72 (–1.04)
• Cash and cash equivalents amounted to SEK 1,960 thousand (1,018)

1 July – 30 Sept 2025

• Net sales amounted to SEK 400 thousand (268)
• Loss after tax amounted to SEK -1,030 thousand (-3,008)
• Earnings per share amounted to SEK -0.12 (–0.35)

Significant events during the reporting period

• Premiere of ZymIQ's dental care products in Asia – new exclusive distribution agreements have been signed with the Malaysian company Pahang Pharmacy Sdn Bhd and the Thai company Thai company Union Medical (Thailand) Co.
• Exclusive distribution agreements for Kalzyme have been signed with KM Vet Pharm Sdn Bhd. in Malaysia and with the Thai company Vet AgriTech CO Ltd.
• A new collaboration has been initiated with the Zoofamiljen store chain in Sweden for the distribution of all Kalzyme products.
• Dr. Mats Clarsund spoke at the Dent2Health Conference in Malmö about ZymIQ's enzyme technology linked to oral health in front of dentists and researchers.

Significant events after the reporting period

• The European Patent Office (EPO) has announced that no opposition has been filed against the company's granted patents EP4380549 linked to ViruPrev.
• ZymIQ has signed a new agreement with last year to drive global expansion and product development.
• Jörgen Thunholm has been recruited as Supply Chain Director ahead of the global launch.
• A reseller agreement for CombatClean Dental Enzyme Tab and K9 Dental Enzyme Spray has been signed with Kynotec GmbH for Austria, Switzerland and Germany.
• The production of our toothbrush tablet has been successfully moved to Sweden, where the test production has been approved, and the cost target has been achieved.